MEDINCELL S.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.76 EUR | 0.00% |
|
-5.63% | +105.00% |
| Jun. 10 | Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024 | |
| Jun. 10 | Medincell: a 'new era' after a 'pivotal' 2023 | CF |
Business Summary
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Number of employees: 138
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Products Received under Development Benefit
58.6
%
| 4 | 97.5 % | 6 | 58.6 % | +45.37% |
Licenses, Milestones
29.3
%
| - | - | 3 | 29.3 % | - |
Royalties
12.0
%
| 0 | 2.5 % | 1 | 12.0 % | +1,077.23% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
France
100.0
%
| 4 | 100.0 % | 10 | 100.0 % | +141.78% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 03-01-08 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 23-08-31 |
| Chief Tech/Sci/R&D Officer | - | 14-12-31 | |
Sébastien Magnat
COO | Chief Operating Officer | - | 16-08-31 |
| Chief Tech/Sci/R&D Officer | - | 07-12-31 | |
Richard Malamut
CTO | Chief Tech/Sci/R&D Officer | 64 | 22-05-08 |
Grace Kim
IRC | Investor Relations Contact | - | 23-09-18 |
| - | - | ||
Julie Alimi
LAW | General Counsel | - | - |
Franck Pouzache
HRO | Human Resources Officer | - | 20-03-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 17-07-04 |
Tone Kvåle
BRD | Director/Board Member | 55 | 22-06-12 |
Virginie Lleu
BRD | Director/Board Member | - | 16-05-24 |
Philippe Guy
CHM | Chairman | - | 10-11-15 |
Elisabeth Kogan
BRD | Director/Board Member | - | 20-12-14 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 28,750,645 | 14,390,274 ( 50.05 %) | 30,646 ( 0.1066 %) | 50.05 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
MEDINCELL S.A. 0.03% | 7,550 | 0.03% | 134,091 $ |
Company contact information
Sector
Sales per Business
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.76
EUR
Average target price
19.24
EUR
Spread / Average Target
+30.35%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +105.00% | 460M | |
| +48.53% | 780B | |
| +41.21% | 627B | |
| -6.37% | 353B | |
| +20.93% | 334B | |
| +8.21% | 296B | |
| +17.49% | 244B | |
| -0.86% | 217B | |
| +11.06% | 214B | |
| +4.40% | 161B |
- Stock Market
- Equities
- MEDCL Stock
- Company MedinCell S.A.
